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ApoE modulation activityHigh throughput screening of a pre-fractionated natural product library identiﬁed 11 active fractions
showing ApoE modulation activity. Mass-directed fractionation of one active crude extract from the
Australian marine sponge Callyspongia sp. resulted in the isolation of 13 metabolites, including three
new bromotyrosine derivatives, callyspongic acid (1), 3,5-dibromo-4-methoxyphenylpyruvic acid (2),
N-acetyl-3-bromo-4-hydroxylphenylethamine (3), and ten known compounds (4–13). The structure
elucidation of compounds 1–3 was based on their 1D and 2D NMR and MS spectroscopic data.
3,5-Dibromo-4-methoxyphenylpyruvic acid (2) showed weak activity in increasing the apolipoprotein
E secretion from human CCF-STTG1 cells at the concentration of 40 lM.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Alzheimer’s disease (AD) has emerged as the most prevalent
form of late-life mental disorder in humans and is typiﬁed by
deposition of b-amyloid (Ab) with the brain.1 Ab is a neurotoxic
peptide and the accumulation of Ab leads to its deposition into pla-
ques and the launching of a pathologic cascade that ultimately
leads to neuronal death.1 An impaired ability to clear Ab peptides
from the brain, rather than increased production of Ab peptides,
is thought to underlie most cases of late-onset AD.2
Apolipoprotein E (ApoE) is the major apolipoprotein in the cen-
tral nervous system that plays a central role in cholesterol trans-
port.3 In the brain, ApoE is mostly produced by astrocytes, and
some of ApoE binds to speciﬁc neuronal receptors for cholesterol
uptake.3 A previous study suggested that increased levels of highly
lapidated ApoE could facilitate the clearance of Ab peptides,4,5
implying that the interference of ApoE secretion could potentially
lead to the treatment of Alzheimer’s disease. Bexarotene is the only
reported compound used clinically that is known to activate ApoE
expression.5
In our ongoing search for new lead compounds for neurodegen-
erative disorders, a drug discovery program was initiated to iden-
tify natural products as ApoE modulators. A high throughput
screening method was developed and used to screen EskitisInstitute’s pre-fractionated natural product library of 102,432 frac-
tions for their ability to modulate ApoE secretion from the human
derived astrocytoma cell line CCF-STTG1, used extensively in
Alzheimer research.6 Eleven fractions were identiﬁed with concen-
tration dependent activity for ApoE enhancement over background
levels, albeit at high concentrations. One of the 11 fractions was
derived from an extract of the Australian sponge Callyspongia sp.
()-LRESIMS of the active fraction showed molecular ions at m/z
349/351/353, 321/323/325, which were predicted to correspond
to bioactive natural products. Mass-directed fractionation of the
CH2Cl2/MeOH extract led to the isolation of 13 compounds, includ-
ing three new bromotyrosine derivatives, callyspongic acid (1),
3,5-dibromo-4-methoxyphenylpyruvic acid (2), and N-acetyl-3-
bromo-4-hydroxylphenylethamine (3), together with ten known
natural products, N-acetyl-3,5-dibromo-4-hydroxyl phenyleth-
amine (4),7 3,5-dibromo-4-methoxyphenylacetic acid (5),8
comantherin (6),9 bastadin 6 (7),10 bastadin 7 (8),10 bastadin 8
(9),11 bastadin 9 (10),11 bastadin 16 (11),12 bastadin 18 (12),13
and bastadin 24 (13).14 Herein we report the isolation and
structure elucidation of callyspongic acid (1), 3,5-dibromo-4-
methoxyphenylpyruvic acid (2), and N-acetyl-3-bromo-4-hydrox-
ylphenylethamine (3), as well as the ApoE modulation activities
of compounds 1–13.
The freeze-dried and ground marine sponge (20.0 g) was
sequentially extracted with n-hexane, CH2Cl2 and MeOH. The
CH2Cl2 and MeOH extracts were combined and chromatographed
3538 L.-W. Tian et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3537–3540on reverse phase C18 ﬂash column, eluting with 10% MeOH/H2O,
30% MeOH/H2O, 50% MeOH/H2O, and 100% MeOH. The 10%
MeOH/H2O was fractionated using reverse phase C18-bonded silica
HPLC (MeOH/H2O/0.1% TFA) to yield 60 fractions. Fractions 22–25
and 29 contained the ions of interest, and yielded 3,5-dibromo-4-
methoxyphenylpyruvic acid (2, 2.0 mg, 0.01% dry wt), and 3,5-
dibromo-4-methoxyphenylacetic acid (5, 0.6 mg, 0.003% dry wt),
respectively. Puriﬁcation of fraction 34 with a Luna C18 semi-pre-
parative HPLC column yielded callyspongic acid (1, 0.2 mg,
0.001% dry wt). The 30% MeOH/H2O fraction was further puriﬁed
by reverse phase C18-bonded silica HPLC (MeOH/H2O/0.1% TFA)
to yield 60 fractions. Fractions 16, 34 and 46 resulted in pure com-
pounds N-acetyl-3-bromo-4-hydroxylphenylethamine (3, 0.4 mg,
0.002% dry wt), N-acetyl-3,5-dibromo-4-hydroxyl phenylethamine
(4, 0.8 mg, 0.004% dry wt), and comantherin (6, 1.0 mg, 0.005% dry
wt). Further puriﬁcation of the fractions 33–36 with a Luna C18
semi-preparative column yielded 3,5-dibromo-4-methoxyphenyl-
acetic acid (6, 0.8 mg, 0.004% dry wt), bastadin 18 (12, 0.4 mg,
0.002% dry wt), and bastadin 24 (13, 0.4 mg, 0.002% dry wt).
Repeated chromatography of 50% MeOH/H2O fraction on reverse
phase C18-bonded HPLC and Luna C18 semi-preparative HPLC
yielded bastadin 6 (7, 0.4 mg, 0.002% dry wt), bastadin 7 (8,
0.3 mg, 0.0015% dry wt), bastadin 8 (9, 0.50 mg, 0.0025% dry wt),
bastadin 9 (10, 0.30 mg, 0.0015% dry wt), and bastadin 16 (11,
0.6 mg, 0.003% dry wt).O
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2'Callyspongic acid (1)15 was obtained as a brown amorphous
powder. The cluster of four isotopic ions at m/z 607/609/611/613
(1:3:3:1) in (+)-LRESIMS indicated the presence of three bromine
atoms in the molecule. The molecular formula, C19H17Br3N2O6,
was established on the basis of HRESIMS (m/z 628.8529 [M+Na]+,
calcd 628.8532 for C19H1779Br3N2O6Na), with 11 degrees of unsat-
uration. The 1H and gHSQC NMR data analysis suggested that com-pound 1 contained three exchangeable protons (dH 12.11, s; 9.98, s;
and 7.87, d, J = 7.9 Hz), ﬁve aromatic protons (dH 7.40, s, 2H; 7.23, d,
J = 2.1 Hz, 1H; 6.92, dd, J = 8.3, 2.1 Hz, 1H; and 6.79, d, J = 8.3 Hz,
1H), one methine (dH 4.44, m), two methylenes (dH 3.73, d,
J = 14.2 Hz, H-70a; 3.70, d, J = 14.2 Hz, H-70b; 3.00, dd, J = 5.0,
14.0 Hz, H-7a; and 2.95, dd, J = 8.2, 14.0 Hz, H-7b), and one meth-
oxy (dH 3.74, s). The gCOSY correlation data (Fig. 1) established a
1,3,4-trisubstituted benzene moiety and an ethylamine group:
NH–CH–CH2. gHMBC experiment revealed the correlations from
the exchangeable proton (dH 9.98) to three aromatic carbons (dC
109.4, C-3; 153.3, C-4; and 116.6, C-5), suggesting that the
hydroxyl group was attached to the C-4 of the 1,3,4-trisubstituted
benzene moiety. gHMBC correlations from the methylene (dH 3.00,
H-7a; 2.95, H-7b) in the ethylamine group to the three aromatic
carbons (dC 130.1, C-1; 133.7, C-2; and 129.8, C-6) indicated that
the ethylamine group was connected to the 3-bromo-4-hydroxy-
benezene moiety. gHMBC correlations from H-7 (dH 3.00, 2.95)
and H-8 (dH 4.44) to a carboxyl carbon (d 173.2) suggested that
the methine H-8 from the ethylamine group was connected to a
carboxyl group. Thus a trisubstituted tyrosine moiety was
assigned. In addition, a two-proton singlet (dH 7.40), characteristic
of a symmetrical 1,3,4,5-tetrasubstituted benzene, showed gHMBC
correlations to the quaternary aromatic carbons (dC 117.6, C-30, 50;
152.6, C-40) and the methylene carbon (dC 28.3, C-70), while the
methylene (dH 3.73, H-70a; 3.70, H-70b) showed gHMBC correla-tions with the aromatic carbons (dC 136.7, C-10; 133.2, C-20, 60),
and two quaternary carbons (dC 151.1, C-80; 163.3, C-90), indicating
an a-oximebenzenepropanamide. The gHMBC correlation from the
methoxy (dH 3.74, s) to the aromatic carbon (dC 152.6) suggested
that methoxy group was attached to the C-4 position of 1,3,4,5-tet-
rasubstituted benzene. The conﬁguration of the oxime was
determined to be E by the diagnostic carbon chemical shift of the
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zylic methylene corresponding to Z oximines are known to be
>35 ppm.16 Finally the connection of the a-oximebenzenepropana-
mide with the substituted tyrosine through an amide bond was
established by the gHMBC correlations from the methine (dH
4.44, H-8) and the exchangeable NH proton (dH 7.87) to the car-
bonyl carbon (dC 163.3) in oximebenzenepropanamide moiety.
Thus, the planar structure of callyspongic acid was elucidated as 1.
The Marfey’s reaction was not performed on compound 1 due to
limited amount of compound obtained. However, the optical rota-
tion of 1 ([a]D23 +3.63, c 0.008, MeOH) was compared with those of
L-3-bromotyrosine ([a]D23 28, c 0.1, MeOH) and D-3-bromotyrosine
([a]D23 +28, c 0.1, MeOH), indicating a D-3-bromotyrosine moiety in
1. D/L-3-bromotyrosine was prepared from corresponding tyrosine
(Fig. 2).
3,5-Dibromo-4-methoxyphenylpyruvic acid (2)17 exhibited a clus-
ter of isotopic ions at m/z 349/351/353 (1:2:1) in the ()-LRESIMS
spectrum, indicating the presence of two bromine atoms in the mol-
ecule. The molecular formula, C10H8Br2O4, was established on the
basis of HRESIMS (m/z 348.8716 [MH], calcd 348.8710 for
C10H779Br2O4), with six degrees of unsaturation. The 1H, and gHSQC
NMR data of compound 2 showed a two-proton singlet (dH 7.79; dC
133.6), representing a symmetrical 1,3,4,5-tetrasubstituted ben-
zene moiety, a methine singlet (dH 6.33; dC 106.5), and a methoxy
(dH 3.77; dC 61.0). The aromatic methine proton (dH 7.79) showed
gHMBC correlations with the aromatic carbons (dC 133.4, C-1;
117.7, C-3/5; and 106.5, C-7) and a sp2 carbon (dC 106.5, C-7). The
methine singlet (dH 6.33) showed gHMBC correlations with aro-
matic carbon (dC 133.6, C-2/6), a sp2 carbon (dC 143.8, C-8), and aTable 1
1H (600 M) and 13C (150 M) NMR data for compounds 1–3 (DMSO-d6)
Position 1
dH dc HMBC dH
1 130.1
2 7.23 d (2.1) 133.7 C3, 4, 6, 7 8.03 s
3 109.4
4 153.3
5 6.79 d (8.3) 116.6 C3, 4, 6
6 6.92 dd (8.3, 2.1) 129.8 C1, 4, 5 8.03 s
7 3.00 dd (14.0, 5.0) 35.2 C1, 2, 8, 9 6.33 s
2.95 dd (14.0, 8.2)
8 4.44 m 54.1 C7, 9
9 173.2
10 136.7
20 7.40 s 133.2 C30 , 60 , 40 , 70
30 117.6
40 152.6
50 117.6
60 7.40 s 133.2 C20 , 30 , 40 , 70
70 3.73 d (14.2) 28.3 C10 , 20 , 80 , 90
3.70 d (14.2)
80 151.1
90 163.3
OCH3 3.74 s 60.9 C40 3.77 s
OH 9.98 s C3, 4, 5
NH 7.87 d (7.9) C8, 90
N–OH 12.11 s C80carbonyl carbon (dC 166.3, C-9). These gHMBC correlation data indi-
cated that compound 2 was very similar to 3-bromo-4-methoxy-
phenylpyruvic acid (enol form).18,19 The methoxy group was
located on the C-4 of the benzene ring by the gHMBC correlations
from the methoxy proton (dH 3.77) to the aromatic carbon
(dC 152.4). Thus, the structure of 2 was assigned as 3,5-dibromo-
4-methoxyphenylpyruvic acid.
N-Acetyl-3-bromo-4-hydroxylphenylethamine (3)20 was iso-
lated as brownamorphous powder. (+)-LRESIMS showed an isotopic
ion cluster at m/z 258/260 (1:1), indicating the presence of one
bromine atom in the molecule. The molecular formula of 3 was
determined to be C10H12BrNO2, on the basis of HRESIMS (m/z
279.9943 [M+Na]+, calcd 279.9940 for C10H1279BrNO2Na). The 1H,
andgHSQCNMRdataof compound3 showed twoexchangeablepro-
tons (dH 9.94 s; 7.82, t, J = 5.6 Hz), three mutually coupled aromatic
protons (dH 7.28, d, J = 2.2 Hz, H-2; 6.98, dd, J = 2.2, 8.2 Hz, H-6; and
6.84, d, J = 8.2 Hz, H-5), twomethylenes (dH 3.18, t, J = 7.3 Hz; 2.56, t,
J = 7.3 Hz), and amethyl group (dH 1.74 s). The above datawere very
similar to those of N-acetyl-3,5-dibromo-4-hydroxyl phenyleth-
amine (4). The only difference was that compound 3 had an 1,3,
4-trisubstitutedbenzene ring insteadof a symmetrical 1,3,4,5-tetra-
substituted benzene ring in 4. Hence, compound 3 was assigned as
N-acetyl-3-bromo-4-hydroxylphenylethamine.
Ten known natural products, namely N-acetyl-3,5-dibromo-4-
hydroxyl phenylethamine (4), 3,5-dibromo-4-methoxyphenylace-
tic acid (5), comantherin (6), bastadin 6 (7), bastadin 7 (8), bastadin
8 (9), bastadin 9 (10), bastadin 16 (11), bastadin 18 (12), and basta-
din 24 (13), were also isolated from the marine sponge. Their struc-
tures were identiﬁed by comparing their 1H and 13C NMR data with
those reported in the literature. Interesting, 3,5-dibromo-4-meth-
oxyphenylpyruvic acid (2) was the rare example of naturally
occurring phenylpyruvic acid (enol) derivatives. This is also the ﬁrst
report of the presence of bastadins from the sponge Callyspongia sp.2 3
dc HMBC dH dc HMBC
133.4 129.4
133.6 C1, 3, 4, 7 7.28 d (2.2) 133.2 C1, 3, 4, 7
117.7 109.6
152.4 152.9
117.7 6.84 d (8.2) 116.7 C1, 3, 4
133.6 C1, 3, 4, 7 6.98 dd (2.2, 8.2) 129.4 C2, 4, 5, 7
106.5 C2, 8, 9 2.56 t (7.3) 34.4 C1, 2, 6, 8
143.8 3.18 t (7.3) 40.8 C1, 7, 10
166.3
169.8
1.74 s 23.4 C10
61.0
9.94 s
7.82 t (5.6) C10
3540 L.-W. Tian et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3537–3540The ApoE modulatory activities of compounds 1–13 were eval-
uated. 3,5-Dibromo-4-methoxyphenylpyruvic acid (2) was the
only active compound, increasing ApoE secretion by one fold over
background at the concentration of 40 lM.
In conclusion, 13 compounds (1–13) were isolated from the
Australian marine sponge Callyspongia sp. Three compounds (1–3)
are new to science and 3,5-dibromo-4-methoxyphenyl-pyruvic acid
(2) show weak ApoE modulation activities. It is the ﬁrst time that
bastadins were isolated from the sponge Callyspongia sp.
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